miércoles, 31 de julio de 2019

Amgen's KRAS-blocking cancer drug shows broader tumor-killing activity

Amgen's KRAS-blocking cancer drug shows broader tumor-killing activity

Go West

STAT Plus: Amgen’s KRAS-blocking cancer drug shows broader tumor-killing activity than previously reported

By ADAM FEUERSTEIN


RUBY WALLAU FOR STAT
Scientists have long known that mutations in a protein called KRAS cause cancer, but discovering drugs capable of blocking KRAS has proven difficult.

No hay comentarios:

Publicar un comentario